Breast cancer (BC) prognosis has dramatically improved in recent decades ([@pkz053-B1],[@pkz053-B2]), in part because of the introduction of biomarker-driven therapies ([@pkz053-B2]). Yet, non-Hispanic black (NHB) women experience a disproportionate burden of poor BC outcomes and are more likely to die from BC than women of any other race or ethnicity ([@pkz053-B7]). Racial disparities in BC-specific mortality vary geographically and are most pronounced in the southeastern region ([@pkz053-B8]). A recent study, conducted using resources from the 500 Cities project, reported that race mortality disparities in Atlanta, Georgia, not only were among the largest in the United States but also had widened between 2005 and 2014 ([@pkz053-B9]), despite national and local efforts to reduce the mortality gap. Although the reported widening disparity is likely an overestimation (due to the small sample size, open cohort design, and an ill-defined source population), with improvements in cancer care, it is increasingly imperative to understand the factors that drive disparate BC outcomes ([@pkz053-B10]).

The available evidence suggests that prognostic disparities are related to a complex combination of biologic ([@pkz053-B15]), treatment ([@pkz053-B18]), and patient-level factors ([@pkz053-B19]) that manifest during both the pre- and post-diagnostic periods ([@pkz053-B20]). Previous investigations have limitedly addressed causal drivers of disparities in single-center studies with small samples, socioeconomically homogenous cohorts, and short or incomplete follow-up. These constraints impede the ability to describe the magnitude of disparities within strata of important factors. More robust population-based studies are needed to examine these complex relationships.

Atlanta represents an ideal setting to evaluate factors contributing to racial disparities in BC-specific mortality. It is a large metropolitan city of nearly 4 million inhabitants with diverse population demographics. According to the 2010 US Census, 32% of the population identified as NHB and 61% as non-Hispanic white (NHW), nearly 27% of Atlanta residents had an income below the poverty level, and 15% lacked health insurance ([@pkz053-B21]). Thus, the primary aims of this study were to assess the tumor, treatment, and patient characteristics that contribute to differences in BC-specific mortality between NHB and NHW women diagnosed with a first primary stage I--IV BC in the metropolitan Atlanta area.

Methods
=======

Study Population
----------------

The Georgia Cancer Registry (GCR) is a statewide population-based registry that has collected all cancer cases diagnosed among Georgia residents since January 1, 1995. Using this registry, we identified NHB and NHW women with a first primary stage I--IV BC diagnosis (*International Classification of Diseases* \[ICD\]-O-3- C50) occurring between January 1, 2010, and December 31, 2014. Women were included if they resided in the metropolitan Atlanta area at the time of diagnosis. All other diagnoses were excluded, including those among other race and/or ethnic groups, patients younger than 18 years, male patients, patients with a previous history of cancer or any secondary tumor diagnoses, and patients with in situ disease. In addition, patients were excluded if diagnosed solely by death certificate or if stage was missing in the registry.

Exposure Assessment
-------------------

Race and ethnicity were obtained from documentation in medical records using classifications similar to the 2010 census. When medical record data were not available, Hispanic ethnicity was determined by the North American Association of Central Cancer Registries Hispanic Identification Algorithm ([@pkz053-B22]), which uses a combination of variables routinely captured by registries (eg, birthplace, race, and names) in addition to Hispanic surname lists from the US Census to classify women as Hispanic or non-Hispanic.

Outcome Assessment
------------------

Underlying cause of death was determined directly from death certificates using ICD-10 codes. The GCR links to the Georgia vital statistics registry annually to identify deaths and causes of death from the preceding year. Additionally, the GCR also links to the US National Death Index each year to identify deaths that occur outside of Georgia. In this study, we included only BC-related deaths recorded through December 31, 2016, because linkage to vital records files were not complete for 2017 at the time the dataset was constructed.

Covariates of Interest
----------------------

*Tumor Characteristics.* Tumor characteristics used in this analysis included cancer stage at diagnosis, tumor grade, expression of the estrogen receptor (ER), expression of the progesterone receptor (PR), and extrapolated molecular subtype. Cancer stage at diagnosis was based on the American Joint Committee on Cancer 7th edition staging manual using combined clinical and pathologic information ([@pkz053-B23]). Tumor grade was categorized as 1, 2, or 3 and above with priority coding for Nottingham or Bloom-Richardson score grades. Hormone receptor expression was classified as positive or negative based on the expression of ER, PR, or both. HER2 expression was similarly classified as positive or negative and has been routinely collected by the GCR since 2010 ([@pkz053-B24]). Molecular subtype was based on the joint expression of hormone receptor and HER2: luminal A (hormone receptor+/HER2−), luminal B (hormone receptor+/HER2+), HER2 overexpressing (hormone receptor−/HER2+), and triple-negative BC (TNBC) was a lack of expression of either tumor biomarker ([@pkz053-B25]).

*Treatment Characteristics.* We considered different treatment modalities as possible contributors to mortality disparities. This included primary surgery (no surgery, breast conserving surgery, or mastectomy) and adjuvant therapy. Adjuvant therapies included receipt of chemotherapy (yes/no), radiation therapy (yes/no), hormone therapy (yes/no, among women diagnosed with ER+ disease), and trastuzumab (yes/no, among women diagnosed with HER2+ disease). In addition to the dates recording initiation of therapy, textual descriptions of the actual antineoplastic agents are captured by the GCR for most cases. Until 2013, HER2-targeted therapies were captured within the chemotherapy variable in GCR; therefore, these textual descriptions were algorithmically searched for each patient to identify records that suggested receipt of HER2-targeted therapy. Thus, patients with an annotation that indicated such therapy were assumed to have received the therapy and those without a corresponding annotation were assumed to not have received the adjuvant therapy.

*Patient Characteristics.* We considered different patient demographic characteristics at the time of diagnosis that may have contributed to disparate cancer outcomes. These included type of health insurance (uninsured, private, Medicaid, and Medicare), age at diagnosis (\<40, 40--49, 50--65, \>65 years), marital status (married, single, divorced, widowed, and/or separated), and socioeconomic status (SES) index for the neighborhood poverty level, based on the census tract of the patient's residence at diagnosis (0%--\<5%, 5%--\<10%, 10%--\<20%, 20%--100%) ([@pkz053-B26]). The tract-level poverty data are published annually from the American Community Survey ([@pkz053-B27]) and have been used widely in population studies ([@pkz053-B28],[@pkz053-B29]).

Statistical Methods
-------------------

Descriptive statistics were calculated for covariates across each population subgroup as median values with a SD, or frequency and proportion within categories. Follow-up was defined as time, in months, from the date of diagnosis until the first of 1) mortality event (due to BC or other cause of death), 2) last date of contact in the registry, or 3) December 31, 2016. Individuals were censored if their last date of contact was before the end of the study period or if they died from any cause unrelated to their BC. We used age-adjusted and multivariable-adjusted Cox proportional hazard models to calculate the hazard ratios (HR) and 95% confidence intervals (CIs) for the association between race and BC-specific mortality ([@pkz053-B30]). We used ln-ln survival curves and an interaction term of each covariate with time to verify the proportional hazards assumption. All variables satisfied the proportional hazards assumption. Potential confounders were determined a priori, based on previous literature and graphical-based methods ([@pkz053-B31],[@pkz053-B32]). Interaction describes differences in the effect of one exposure across strata of another exposure, which depends on the scale. In this analysis, we assessed additive and multiplicative interaction for the effect of race on BC mortality by patient, tumor, and treatment characteristics. To assess the presence of interaction between race and the characteristics of interest, we used the common referent approach to calculate the relative excess risk due to interaction (RERI), evaluating departure of the effect on the additive scale, indicating that the combined effect of the two exposures is greater than the sum of the individual effects ([@pkz053-B33]). We used the delta method to calculate the corresponding 95% confidence interval using the variance-covariance matrix from the effect estimates ([@pkz053-B34]). The presence of multiplicative interactions, indicating that the combined effect of the exposures is greater than the product of the individual effects, was assessed using the likelihood ratio test, with interaction terms included in the model and stratum-specific effect estimates reported.

Our graphical assessment of potential confounders showed that all covariates of interest were on the causal path between race and BC-specific mortality ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, available online). Models were thus adjusted for age only. We additionally performed sensitivity analyses, adjusting for tumor and treatment characteristics. Because the covariates of interest were on the causal path, we used mediation techniques to evaluate the role of stage, subtype, and SES as intermediates on the path between race and BC-specific mortality ([@pkz053-B35]), employing the multiple mediation analysis R package to account for the categorical mediators ([@pkz053-B36],[@pkz053-B37]). Mediation techniques have been developed to quantify the direct and indirect effects of an exposure on an outcome through intermediates of interest. All analyses were carried out using R version 13.1 and SAS version 9.4 (Cary, NC).

Results
=======

We identified 3580 NHB and 4943 NHW women diagnosed with a first primary BC between 2010 and 2014 in the metropolitan Atlanta area ([Table 1](#pkz053-T1){ref-type="table"}). On average, women were followed for 3.5 years, range 0--7 years. We observed 488 BC-specific deaths among NHB women and 319 BC-specific deaths among NHW women. Compared to NHW BC patients, NHB women were more likely to be diagnosed at a younger age (\<55 years: 46% vs 37%), with higher stage (stage IV: 9.4% vs 4.8%), grade (grade 3+: 45% vs 27%), node positive (33% vs 26%), and triple-negative tumors (18% vs 8.1%). NHB women were also more likely to receive neoadjuvant therapy (16% vs 9.9%) and chemotherapy (57% vs 40%). With respect to patient characteristics, NHB women were less likely to be married at the time of diagnosis (35% vs 61%) and more likely to live in a high-poverty neighborhood at diagnosis (45% vs 13%, 20--100% poverty index). In the metropolitan-Atlanta area, we observed an overall age-adjusted hazard ratio of 2.35 (95% CI = 2.04 to 2.72) comparing the BC specific mortality hazard in NHB women with NHW women (data not shown).

###### 

Patient demographic and clinicopathological characteristics among non-Hispanic white (NHW) and non-Hispanic black (NHB) women diagnosed with breast cancer in the metropolitan Atlanta area 2010--2014 and registered with the Georgia Cancer Registry

  Characteristic                                                                                  NHW            NHB
  ----------------------------------------------------------------------------------------------- -------------- --------------
  Age at diagnosis, median (SD), y                                                                60 (13.3)      56 (13.0)
  Length of follow-up, median (SD), months                                                        44.6 (20.6)    42 (20.8)
  Time to event, median (SD), months                                                              23.33 (18.4)   20.87 (16.9)
  Breast cancer-specific deaths, no. (%)                                                          319 (6.5)      488 (14)
  Age, no. (%), y                                                                                                
   \<55                                                                                           1807 (37)      1632 (46)
   ≥55                                                                                            3136 (63)      1948 (54)
  AJCC stage, no. (%)                                                                                            
   I                                                                                              2727 (55)      1397 (39)
   II                                                                                             1537 (31)      1341 (37)
   III                                                                                            444 (9.0)      505 (14)
   IV                                                                                             235 (4.8)      337 (9.4)
  Tumor grade, no. (%)                                                                                           
   1                                                                                              1313 (27)      476 (13)
   2                                                                                              2052 (42)      1275 (36)
   3+                                                                                             1344 (27)      1608 (45)
   Unknown                                                                                        234 (4.7)      221 (6.2)
  Tumor size, no. (%), cm                                                                                        
   ≤0.5                                                                                           564 (11)       305 (8.5)
   0.6--1                                                                                         869 (18)       427 (12)
   \>1 to \<5                                                                                     3085 (62)      2237 (62)
   ≥5                                                                                             356 (7.2)      522 (15)
   Unknown                                                                                        69 (1.4)       89 (2.5)
  Lymph node, no. (%)                                                                                            
   Node negative                                                                                  3181 (64)      1899 (53)
   Node positive                                                                                  1307 (26)      1175 (33)
   1--3                                                                                           904 (18)       715 (20)
   ≥4                                                                                             279 (5.6)      254 (7.1)
   Unknown number                                                                                 124 (2.5)      206 (5.8)
   No nodes examined                                                                              450 (9.1)      494 (14)
   Unknown node status                                                                            5 (0.1)        12 (0.4)
  Estrogen receptor status, no. (%)                                                                              
   ER− tumor                                                                                      640 (13)       912 (25)
   ER+ tumor                                                                                      4248 (86)      2614 (73)
   Unknown/Borderline                                                                             55 (1.1)       54 (1.5)
  Molecular subtype, no. (%)                                                                                     
   HR+/HER2− (luminal A)                                                                          3511 (71)      2074 (58)
   HR+/HER2+ (luminal B)                                                                          525 (11)       432 (12)
   HR-/HER2+ (HER2 overexpressing)                                                                172 (3.5)      185 (5.2)
   HR-/HER2− (triple negative)                                                                    401 (8.1)      646 (18)
   Unknown                                                                                        334 (6.8)      243 (6.8)
  Receipt of surgery, no. (%)                                                                                    
   Breast conserving surgery                                                                      2492 (50)      1600 (45)
   Mastectomy                                                                                     2105 (53)      1450 (41)
   Unknown/None                                                                                   346 (7.0)      530 (15)
  Receipt of neoadjuvant therapy, no. (%)                                                                        
   Yes                                                                                            491 (9.9)      563 (16)
   No                                                                                             4452 (90)      3017 (84)
  Receipt of chemotherapy, no. (%)                                                                               
   Yes                                                                                            1962 (40)      2035 (57)
   No                                                                                             2926 (59)      1483 (41)
   Unknown                                                                                        55 (1.1)       62 (1.7)
  Receipt of radiation, no. (%)                                                                                  
   Yes                                                                                            2805 (57)      2002 (56)
   No                                                                                             1974 (40)      1368 (38)
   Unknown                                                                                        164 (3.3)      210 (5.9)
  Receipt of hormone therapy (among ER+ tumors only),[\*](#tblfn1){ref-type="table-fn"} no. (%)                  
   Yes                                                                                            3426 (81)      2059 (79)
   No                                                                                             822 (19)       555 (21)
  Receipt of trastuzumab (among HER2+ tumors only),[\*](#tblfn1){ref-type="table-fn"} no. (%)                    
   Yes                                                                                            481 (69)       445 (72)
   No                                                                                             216 (31)       172 (28)
  Marital status, no. (%)                                                                                        
   Single                                                                                         615 (12)       1109 (31)
   Married (common law and unmarried domestic)                                                    3025 (61)      1258 (35)
   Divorced                                                                                       547 (11)       596 (17)
   Widowed                                                                                        590 (12)       383 (11)
   Separated                                                                                      23 (0.5)       64 (1.8)
   Unknown                                                                                        143 (2.9)      170 (4.8)
  SES index, no. (%)                                                                                             
   0--\<5% poverty                                                                                1529 (31)      211 (5.9)
   5--\<10% poverty                                                                               1469 (30)      455 (13)
   10--\<20% poverty                                                                              1320 (26)      1297 (36)
   20--100% poverty                                                                               625 (13)       1617 (45)
  Insurance type, no. (%)                                                                                        
   Uninsured                                                                                      57 (1.2)       144 (4.0)
   Private                                                                                        3101 (63)      1953 (55)
   Medicaid                                                                                       139 (2.8)      516 (14)
   Medicare                                                                                       1545 (31)      844 (24)
   Military/Other[†](#tblfn2){ref-type="table-fn"}                                                39 (0.8)       65 (1.8)
   Unknown                                                                                        62 (1.3)       58 (1.6)

Data abstracted from text fields of Georgia Cancer Registry database. AJCC = American Joint Committee on Cancer; ER = estrogen receptor; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; SES = socioeconomic status.

Mostly military; n = 8 other among NHB; n = 0 other among NHW.

Tumor Characteristics
---------------------

We observed a consistent disparity in BC deaths between NHB women and NHW women within strata of diagnostic stage ([Table 2](#pkz053-T2){ref-type="table"}). There was a departure from additivity of the RERI for each increase in stage classification, with the most pronounced effect observed among NHB women with stage IV disease (RERI = 57, 95% CI = 27 to 88). We found similar effects for tumor grade at diagnosis. Among NHB women diagnosed with ER+ disease, we observed 2.49 times the hazard of BC mortality compared to NHW women (95% CI = 2.07 to 2.99). Within strata of molecular subtype, we observed consistent disparities indicating more than a twofold hazard of BC mortality among NHB patients diagnosed with luminal A, luminal B, or HER2-overexpressing tumors. The smallest relative disparity was among women diagnosed with TNBC (HR = 1.36, 95% CI = 1.01 to 1.82). With exception of stage, multivariable models showed similar trends but had attenuated effect estimates ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}, available online).

###### 

Age-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer (BC)-specific death according to race and tumor characteristics among non-Hispanic White (NHW) and non-Hispanic Black (NHB) women diagnosed with BC in the metropolitan Atlanta area 2010--2014 and registered with the Georgia Cancer Registry

  Characteristic         No. deaths   Common referent HR (95% CI)   RERI (95% CI)               Stratified effects     Stratified effects[\*](#tblfn3){ref-type="table-fn"}                        
  ---------------------- ------------ ----------------------------- ------------------------ ------------------------ ------------------------------------------------------ --------------------- ---------------------
  Stage                                                                                                                                                                                            
   I                     31           29                            Referent                   1.97 (1.19 to 3.26)                             ---                            2.08 (1.26 to 3.43)   1.13 (0.63 to 2.01)
   II                    80           118                           4.75 (3.13 to 7.21)        8.96 (6.02 to 13.35)                    3.25 (1.01 to 5.49)                    1.89 (1.41 to 2.53)   1.42 (1.04 to 1.95)
   III                   85           126                           18.85 (12.43 to 28.59)    29.97 (20.14 to 44.61)                  10.16 (2.52 to 17.79)                   1.57 (1.17 to 2.09)   1.24 (0.90 to 1.71)
   IV                    123          215                           69.59 (46.43 to 104.3)    127.7 (87.01 to 187.4)                  57.13 (26.5 to 87.75)                   1.73 (1.34 to 2.22)   1.57 (1.19 to 2.06)
  *P* ~Interaction~                                                                                                                                                                   .81                   .47
  Grade                                                                                                                                                                                            
   1                     20           14                            Referent                   1.92 (0.96 to 3.87)                             ---                            1.99 (0.98 to 4.03)   1.74 (0.70 to 4.29)
   2                     97           119                           3.02 (1.86 to 4.91)        6.54 (4.06 to 10.53)                    2.59 (0.73 to 4.46)                    2.21 (1.67 to 2.92)   1.72 (1.26 to 2.35)
   3+                    154          286                           8.24 (5.16 to 13.16)      14.43 (9.15 to 22.76)                    5.26 (2.18 to 8.34)                    1.71 (1.40 to 2.10)   1.14 (0.92 to 1.42)
  *P* ~Interaction~                                                                                                                                                                   .38                   .06
  ER status                                                                                                                                                                                        
   ER+                   209          282                           Referent                   2.45 (2.03 to 2.95)                             ---                            2.49 (2.07 to 2.99)   1.62 (1.31 to 2.00)
   ER-                   90           189                           3.37 (2.61 to 4.34)        5.32 (4.34 to 6.52)                     0.51 (−0.58 to 1.59)                   1.57 (1.21 to 2.02)   1.15 (0.86 to 1.53)
  *P* ~Interaction~                                                                                                                                                                  .007                   .08
  Molecular subtype                                                                                                                                                                                
   Luminal A             171          221                           Referent                   2.42 (1.98 to 2.95)                             ---                            2.43 (1.99 to 2.97)   1.58 (1.25 to 1.98)
   Luminal B             31           56                            1.37 ( 0.93 to 2.01)       3.26 (2.40 to 4.43)                     0.48 (−0.56 to 1.52)                   2.57 (1.66 to 3.98)   1.53 (0.96 to 2.45)
   HER2 overexpressing   16           40                            2.29 (1.37 to 3.83)        5.59 (3.96 to 7.91)                     1.88 (−0.21 to 3.98)                   2.51 (1.41 to 4.46)   1.69 (0.87 to 3.30)
   TNBC                  65           137                           3.92 (2.94 to 5.22)        5.46 (4.35 to 6.85)                     0.12 (−1.24 to 1.49)                   1.36 (1.01 to 1.82)   1.09 (0.78 to 1.53)
  *P* ~Interaction~                                                                                                                                                                   .02                   .16

Adjusted for age; stage; subtype; receipt of surgery, chemotherapy, radiation, hormone therapy, and trastuzumab; insurance status. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; RERI = relative excess risk due to interaction; TNBC = triple-negative BC.

Treatment Characteristics
-------------------------

Race disparities were pronounced within strata across all treatment modalities ([Table 3](#pkz053-T3){ref-type="table"}). We observed multiplicative interaction for the type of surgery received and receipt of chemotherapy, the former likely driven by women with stage IV disease who did not undergo surgery. In age-adjusted models, we did identify additive interaction between receipt of hormone therapy (among women with ER+ disease) and race and/or ethnicity (RERI = 0.90, 95% CI = 0.77 to 1.04). Similar additive interactive effects were found for receipt of radiation therapy (RERI = 1.40, 95% CI = 0.61 to 2.19). In the multivariable-adjusted models, we observed similar, although attenuated, effect estimates ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}, available online).

###### 

Age-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer (BC)-specific death according to race and treatment parameters among non-Hispanic white (NHW) and non-Hispanic black (NHB) women diagnosed with BC in the metropolitan Atlanta area 2010--2014 and registered with the Georgia Cancer Registry

  Characteristic                                 No. deaths   Common referent HR (95% CI)   RERI (95% CI)           Stratified effects    Stratified effects[\*](#tblfn4){ref-type="table-fn"}                        
  ---------------------------------------------- ------------ ----------------------------- ---------------------- --------------------- ------------------------------------------------------ --------------------- ---------------------
  Surgery                                                                                                                                                                                                             
   No.                                           139          241                           Referent                1.30 (1.03 to 1.64)                           ---                            1.27 (1.01 to 1.61)   1.38 (1.07 to 1.78)
   Breast conserving surgery                     59           76                            0.04 (0.03 to 0.06)     0.08 (0.06 to 0.11)                  −0.26 (−0.55 to 0.04)                   2.12 (1.49 to 3.00)   1.44 (0.96 to 2.15)
   Mastectomy                                    121          171                           0.10 (0.08 to 0.14)     0.23 (0.18 to 0.30)                  −0.17 (−0.45 to 0.11)                   2.25 (1.77 to 2.85)   1.39 (1.07 to 1.80)
  *P* ~Interaction~                                                                                                                                                                                      .02                   .98
  Chemotherapy                                                                                                                                                                                                        
   No                                            103          124                           0.34 (0.26 to 0.44)     0.97 (0.75 to 1.25)                  −0.33 (−0.70 to 0.03)                   3.00 (2.26 to 3.97)   1.63 (1.17 to 2.27)
   Yes                                           171          317                           Referent                1.96 (1.62 to 2.38)                           ---                            1.92 (1.59 to 2.32)   1.38 (1.12 to 1.71)
  *P* ~Interaction~                                                                                                                                                                                      .09                   .03
  Radiation                                                                                                                                                                                                           
   No                                            164          238                           1.868 (1.46 to 2.38)    4.73 (3.78 to 5.91)                   1.40 (0.61 to 2.19)                    2.64 (2.14 to 3.27)   1.29 (0.62 to 2.64)
   Yes                                           130          205                           Referent                2.46 (1.96 to 3.09)                           ---                            2.28 (1.81 to 2.86)   1.53 (1.19 to 1.96)
  *P* ~Interaction~                                                                                                                                                                                      .69                   .68
  Receipt of hormone therapy (ER+ tumors only)                                                                                                                                                                        
   No                                            161          267                           1.93 (1.43 to 2.60)     4.73 (3.62 to 6.19)                   0.90 (0.77 to 1.04)                    2.36 (1.72 to 3.25)   1.36 (0.96 to 1.93)
   Yes                                           158          221                           Referent                2.47 (1.97 to 3.09)                           ---                            2.50 (1.99 to 3.13)   1.84 (1.42 to 2.38)
  *P* ~Interaction~                                                                                                                                                                                      .98                   .37
  Receipt of trastuzumab (HER2+ tumors only)                                                                                                                                                                          
   No                                            283          414                           1.36 (0.76 to 2.44)     3.68 (2.24 to 6.05)                   0.63 (−0.88 to 2.13)                   2.64 (1.53 to 4.55)   1.29 (0.63 to 2.64)
   Yes                                           36           74                            Referent                2.69 (1.70 to 4.26)                           ---                            3.37 (1.59 to 7.14)   1.97 (1.17 to 3.32)
  *P* ~Interaction~                                                                                                                                                                                      .99                   .33

Adjusted for age; stage; subtype; receipt of surgery, chemotherapy, radiation, hormone therapy, and trastuzumab; insurance status. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; RERI = relative excess risk due to interaction.

Patient Characteristics
-----------------------

BC-specific mortality disparities by race and patient characteristics are provided in [Table 4](#pkz053-T4){ref-type="table"}. We observed the most pronounced disparity among patients with private insurance at diagnosis (HR = 2.46, 95% CI = 1.98 to 3.07) and Medicare (HR = 2.24, 95% CI = 1.74 to 2.90). We observed a larger disparity among married women (HR = 2.71, 95% CI = 2.13 to 3.45). However, there was no evidence of effect modification by marital status or departure from additivity. Among individuals living in the highest SES index, we observed that NHB women had 2.67 times the hazard compared to their NHW counterparts (95% CI = 1.65 to 4.33). Conversely, among women with no insurance and in the lowest SES index, we observed less pronounced disparities (HR = 1.56, 95% CI = 0.71 to 3.43 and HR = 1.90, 95% CI = 1.39 to 2.59, respectively). In the multivariable-adjusted models, we observed similar, but attenuated, effect estimates ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}, available online).

###### 

Age-adjusted and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for breast cancer (BC)-specific death according to race and patient characteristics among non-Hispanic white (NHW) and non-Hispanic black (NHB) women diagnosed with BC in the metropolitan Atlanta area 2010--2014 and registered with the Georgia Cancer Registry

  Characteristic                                     No. deaths   Common referent HR (95% CI)       RERI (95% CI)      Stratified effects   Stratified effects[†](#tblfn6){ref-type="table-fn"}                         
  -------------------------------------------------- ------------ ----------------------------- --------------------- --------------------- ----------------------------------------------------- --------------------- ---------------------
  Insurance type[\*](#tblfn5){ref-type="table-fn"}                                                                                                                                                                      
   Uninsured                                         8            36                             3.84 (1.88 to 7.84)   6.09 (4.10 to 9.04)  0.77 (−2.69 to 4.23)                                   1.56 (0.71 to 3.43)   1.15 (0.46 to 2.86)
   Private insurance                                 147          212                                 Referent         2.47 (1.98 to 3.07)  ---                                                    2.46 (1.98 to 3.07)   1.61 (1.28 to 2.03)
   Medicaid                                          18           93                             3.18 (1.92 to 5.27)   4.56 (3.48 to 5.97)  −0.09 (−1.92 to 1.74)                                  1.44 (0.87 to 2.37)   1.27 (0.75 to 2.16)
   Medicare                                          133          131                            1.56 (1.17 to 2.07)   3.41 (2.61 to 4.46)  0.38 (−0.40 to 1.16)                                   2.24 (1.74 to 2.90)   1.45 (1.09 to 1.93)
  *P* ~Interaction~                                                                                                                                                                                        .33                   .28
  Age group, y                                                                                                                                                                                                          
   \<40                                              15           49                             0.66 (0.38 to 1.14)   1.75 (1.25 to 2.46)  0.02 (−0.72 to 0.76)                                   2.68 (1.48 to 4.85)   1.68 (0.93 to 3.03)
   40--49                                            39           102                            0.55 (0.38 to 0.79)   1.56 (1.20 to 2.05)  −0.06 (−0.62 to 0.49)                                  2.85 (1.95 to 4.16)   1.54 (0.99 to 2.39)
   50--65                                            124          210                            0.65 (0.50 to 0.84)   1.62 (1.29 to 2.04)  −0.11 (−0.61 to 0.39)                                  2.50 (1.99 to 3.16)   1.43 (1.09 to 1.86)
   \>65                                              141          127                                 Referent         2.08 (1.61 to 2.68)  ---                                                    2.06 (1.60 to 2.66)   1.35 (1.01 to 1.80)
  *P* ~Interaction~                                                                                                                                                                                        .59                   .63
  Marital status                                                                                                                                                                                                        
   Married                                           139          144                                 Referent         2.82 (2.21 to 3.60)  ---                                                    2.71 (2.13 to 3.45)   1.79 (1.37 to 2.34)
   Single                                            47           170                            1.64 (1.15 to 2.32)   3.87 (3.05 to 4.89)  0.41 (−0.51 to 1.33)                                   2.26 (1.61 to 3.17)   1.49 (1.03 to 2.17)
   Divorced/widowed/separated                        116          143                            1.94 (1.48 to 2.53)   3.12 (2.44 to 3.98)  −0.64 (−1.50 to 0.21)                                  1.51 (1.17 to 1.96)   1.07 (0.79 to 1.45)
  *P* ~Interaction~                                                                                                                                                                                        .01                   .07
  SES index                                                                                                                                                                                                             
   0--\<5% poverty                                   71           25                                  Referent         2.90 (1.78 to 4.73)  ---                                                    2.67 (1.65 to 4.33)   2.26 (1.26 to 4.06)
   5--\<10% poverty                                  96           57                             1.44 (1.04 to 1.99)   3.17 (2.20 to 4.58)  −0.16 (−1.70 to 1.37)                                  2.07 (1.47 to 2.90)   1.17 (0.76 to 1.79)
   10--\<20% poverty                                 99           167                            1.61 (1.16 to 2.23)   3.23 (2.40 to 4.35)  −0.27 (−1.67 to 1.12)                                  1.88 (1.44 to 2.44)   1.32 (0.97 to 1.80)
   20--100% poverty                                  53           239                            1.86 (1.27 to 2.71)   3.72 (2.80 to 4.94)  −0.04 (−1.47 to 1.40)                                  1.90 (1.39 to 2.59)   1.29 (0.92 to 1.81)
  *P* ~Interaction~                                                                                                                                                                                        .61                   .41

Military/other not estimated due to cell size. RERI = relative excess risk due to interaction; SES = socioeconomic status.

Adjusted for age; stage; subtype; receipt of surgery, chemotherapy, radiation, hormone therapy, and trastuzumab; insurance status.

Mediation Analysis
------------------

Based on our graphical depiction of the underlying paths relating race to BC-specific mortality, we evaluated the role of stage, subtype, and SES as mediators to the underlying disparities. In our mediation analysis, we observed that 68% (95% CI = 52% to 83%) of the excess BC-specific mortality was mediated through stage, subtype, and SES, controlling for age at diagnosis ([Table 5](#pkz053-T5){ref-type="table"}). Given that advanced stage at diagnosis appeared to drive the association, we also performed a sensitivity analysis among stage I--III diagnoses. The total proportion mediated through these three factors remained approximately 68%, although the relative proportion mediated through SES increased (data not shown).

###### 

Age-adjusted hazard models and 95% confidence intervals (CIs) for the mediating effects of subtype, stage, and socioeconomic status (SES) index on the association between race and breast cancer-specific death among non-Hispanic white (NHW) and non-Hispanic black (NHB) women diagnosed with breast cancer in the metropolitan Atlanta area 2010--2014 and registered with the Georgia Cancer Registry

  Mediator        P(M\|E)[\*](#tblfn7){ref-type="table-fn"}   Indirect effect[†](#tblfn8){ref-type="table-fn"}   \% mediated
  --------------- ------------------------------------------- -------------------------------------------------- ---------------------
  Subtype         0.58                                        0.11 (0.09 to 0.14)                                12 (8.8 to 15.8)
  0.12                                                                                                           
  0.05                                                                                                           
  0.18                                                                                                           
  Stage           0.39                                        0.45 (0.36 to 0.52)                                47.3 (38.2 to 57.1)
  0.37                                                                                                           
  0.14                                                                                                           
  0.094                                                                                                          
  SES index       0.059                                       0.09 (0.00 to 0.20)                                8.9 (0.0 to 18.1)
  0.13                                                                                                           
  0.36                                                                                                           
  0.45                                                                                                           
  Direct effect                                               0.32 (0.14 to 0.51)                                ---
  Total effect                                                0.96 (0.7 to 1.14)                                 68 (53 to 89)

Probability of each mediator among NHB women. HR = hazard ratio.

Effect on outcome through mediator on log scale.

Discussion
==========

Consistent with previous reports on racial disparities in BC-specific mortality, our study illustrates substantial disparities between NHB and NHW women diagnosed with BC in the metropolitan Atlanta area. Providing a more robust picture of the public health problem, our study broadly examined the contributions of tumor, treatment, and patient characteristics to the disparity, identifying potential targets for further exploration and---ultimately---intervention. Our interaction models showed the most pronounced effect estimates among lower stage, ER+, and luminal breast tumors. In nearly all analyses, disparities were exacerbated in the referent category, or group that is typically thought to have the best prognosis. Although racial disparities in BC mortality have been attributed to black women more likely being diagnosed at a later stage or with TNBC subtype, we observed the least pronounced racial disparities among patients with tumors that carry less favorable prognosis, such as TNBC subtype and high stage at diagnosis.

Tumors with a favorable prognosis are those with low stage, limited lymph node involvement, and expression of ER at diagnosis. Racial disparities in these tumors might suggest that downstream characteristics from diagnosis may be important to better understand and address the disparity. Consistent with our findings, a study that examined racial disparities within ER- and/or PR-positive tumors among NHB and NHW women in Chicago reported a fourfold increase in hazard of death for NHB women (95% CI = 1.76 to 10.9) ([@pkz053-B38],[@pkz053-B39]). Tumors with positive expression of hormone receptor are amenable to biomarker-driven therapies; however, a recent study has suggested that NHB women are less likely to be adherent to adjuvant endocrine therapy, which may be related to prognosis ([@pkz053-B40]). Further, data among NHB and NHW women diagnosed with luminal A disease in an equal-access health-care system (Kaiser Permanente) showed no disparities in BC-specific mortality ([@pkz053-B41]). These findings may suggest that outcome disparities among NHB women with luminal A tumors are largely attributable to social and structural inequities ([@pkz053-B42]) and warrant further investigation ([@pkz053-B43],[@pkz053-B44]).

Our results, as well as others, have identified stage as an important contributor to the disparity. This is evident among NHB women who are consistently diagnosed at a later stage, which is one important aspect of the disparity. However, our age-adjusted models showed the most pronounced relative mortality disparity among stage I breast tumors, which was strongly attenuated after adjusting for covariates in the sensitivity analysis. These results may be driven by the low baseline risk of mortality in these women and may also suggest that treatment-related factors (timely receipt of therapy or adherence) are drivers of the observed disparity in early stage tumors. Additional efforts are needed to understand why NHB women are consistently diagnosed with later stage, despite self-report of comparable mammography rates among NHB women in national surveys ([@pkz053-B8],[@pkz053-B45]), and what downstream factors from diagnosis are affecting the disparity in women diagnosed with low-stage breast carcinomas.

In a recent study by Warner et al. ([@pkz053-B46]), the authors reported that molecular subtype, stage, body mass index (BMI), and insurance were important contributors to BC mortality disparities. We similarly identified stage and subtype as important contributors, in addition to SES index---accounting for nearly 68% of the disparity. BMI is not readily available in registry data, thus we were unable to examine the extent to which it mediates the association between race and BC mortality disparities. Although an important contribution to the literature, Warner et al. used the National Cancer Database, which includes women diagnosed with BC in various sites around the United States and may not be representative of the experience of women diagnosed with BC in the southeastern United States. Given that race is a social construct that encompasses a lived experience that does not have a counterfactual condition, it is important to identify modifiable factors that mediate the observed effect and could serve as targets for intervention within the social contexts' that people live ([@pkz053-B47]).

Although racial disparities in BC mortality are well documented, there exists substantial geographic heterogeneity, which reflects the distinct social conditions, local policies, cultural norms, and institutional environments throughout the United States. A meta-analysis of 20 studies reported that NHB women were 19% more likely to die from BC than their NHW counterparts ([@pkz053-B48]). This meta-estimate suggests that there is an observed disparity; however, it is much less than what we observed in our study. The Carolina Breast Cancer Study has reported results that are more consistent with what we observed, with a hazard ratio of 1.9 comparing NHB to NHW women among those diagnosed with a luminal A subtype (95% CI = 1.3 to 2.8) ([@pkz053-B49]). The similarity of our results with the Carolina Breast Cancer Study may suggest that distal factors related to the environment may be important contributors to differences in outcomes. These include systemic and political environments that may be more likely to occur in the southeastern United States compared to elsewhere in the United States. Health-care access, systemic racism, and receipt of guideline-concordant care could be important macro-level factors to consider in future studies.

Our study has many strengths, namely, that it leverages resources from a high-quality population-based registry among a well-defined source population. Using this information-rich data source, we were able to examine specific tumor, treatment, and patient characteristics and their contribution to BC-specific mortality. Limitations should also be considered. Trastuzumab is not recorded directly in the database and was abstracted from text fields for the purposes of this study. We expect that any patient with a recorded indication for trastuzumab would have received it, whereas, women who did not have an indication for the therapy in the text fields could have received the therapy, but these data were not recorded. In our study, approximately 70% of HER2+ women had an indication for HER2 targeted therapy, which is comparable to the proportion of ER+ women receiving endocrine therapy in SEER-Medicare linked studies ([@pkz053-B50]). Still, further validation is needed. Additionally, we were unable to assess guideline receipt of the various treatment modalities or adherence to endocrine therapy, which may be important contributors to the observed differences in short-term disparities. Finally, we did not have access to information related to individual-level factors such as income, BMI, or medical and mental health complexity, which will be essential in future analyses.

Although prognostic disparities in BC are related to a complex combination of biologic, treatment, and patient-level factors, we demonstrated that there could be drivers that are amenable to intervention. Although the increased incidence rate of TNBC among NHB women has received attention, because these tumors have a poorer prognosis, our results also highlight the importance of hormonally responsive tumors as primary drivers of the disparity, which already have established and effective treatment regimens. Luminal subtypes are the most prevalent tumors among African-American women, comprising approximately 75% of all BC diagnoses ([@pkz053-B7]). Effectively treating women with ER+ tumors could substantially impact race disparities in the metropolitan Atlanta area. Further understanding of differences in receipt of guideline-concordant care, treatment delay and completion, and biologic factors that may affect response to treatment and prognosis are needed to improve patient outcomes.
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